Search results
Showing 556 to 570 of 1331 results for heart OR cardi* OR arrythmia
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Cardiac resynchronisation therapy for the treatment of heart failure (TA120)
This guidance has been updated and replaced by NICE technology appraisal guidance 314.
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
Infliximab for acute exacerbations of ulcerative colitis (TA163)
Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
Cardiac contractility modulation device implantation for heart failure (IPG655)
We have moved interventional procedures guidance 655 to become HealthTech guidance 520. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
CytoSorb for reducing risk of bleeding during cardiac surgery
Topic prioritisation
applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number
applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number
applicable) Source guidance details Comes from guidance Heart valve disease presenting in adults: investigation and management Number